PriyaPatel
“`
TLDR:
- LinkGevity awarded Women TechEU grant for AI-driven drug discovery
- Company uses proprietary Blueprint Theory of Aging for innovative approach to drug discovery
Article:
LinkGevity, an AI-driven drug discovery company focused on longevity and age-related disease, has been awarded a Women TechEU grant funded through Horizon Europe, recognizing its groundbreaking work in tackling age-related diseases. The company leverages the Blueprint Theory of Aging to identify key pathological pathways shared across multiple diseases, allowing for the development of broad-spectrum therapeutics. LinkGevity’s technology has already produced a promising “Anti-Necrotic” therapeutic that targets a vital biological pathway linked to major causes of death globally.
Co-founders Dr. Carina Kern and Serena Kern Libera emphasize the importance of their mission to revolutionize drug discovery and address the rise of age-related diseases. The Women TechEU grant aims to support Europe’s most promising women-led deep tech startups, offering funding, mentoring, coaching, and training opportunities to accelerate development and market entry.
LinkGevity’s AI-driven platform challenges traditional drug discovery approaches by targeting shared molecular pathways across diseases, offering comprehensive treatments for multifaceted conditions. The company’s innovative solutions have caught the attention of organizations like NASA’s Space-H program, highlighting the potential impact of their research beyond traditional healthcare settings.
With a focus on licensing its IP to global pharma and life science companies, LinkGevity’s Blueprint Theory of Aging integrates insights from various disciplines to accurately identify and target key biological pathways involved in aging. The company’s Angel round of funding is dedicated to advancing its Anti-Necrotic technology and further developing its technological platform at the Babraham Research Campus in Cambridge, UK.
AI-driven drug discovery is crucial in addressing the complex nature of age-related diseases, which are multifactorial and require a more comprehensive approach. By identifying and targeting core biological pathways shared across diseases, AI technology can lead to more effective treatments that address the root causes of multiple conditions simultaneously.
Media Contacts:
Serena Kern-Libera, COO
serena@linkgevity.com
Scius Communications
Katja Stout +447789435990
katja@sciuscommunications.com
Daniel Gooch +447747875479
daniel@sciuscommunications.com
“`
